Related to this topic:  | Online VideosWeblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Moyamoya Disease

Recognised in Japan in the 1960s, this is a progressive occlusive cerebral arteritis affecting the distal internal carotid arteries near the Circle of Willis. Moyamoya is Japanese for "puff of smoke" and describes the appearance of the resultant network of abnormal small collateral vessels seen on angiography. There is a familial form which links to a gene on chromosome 17q25 - though the exact underlying cause remains unknown.

Epidemiology

Incidence

Moyamoya Disease (MMD) is a rare condition. It is commoner in Asians and in girls. One study in Japan which screened 11,402 healthy people found that the percentage with asymptomatic MMD identified by MRI and magnetic resonance angiography was 0.07% for the total group, 0.05% in men and 0.10% in women. The female to male ratio was 3.3:1, with a mean age of 54.0 years. Estimates of the prevalence of MMD in the Japanese population were calculated as 50.7 per 100,000 people; 28.9 in men and 94.3 in women. 1

Presentation

Generally the clinical features are those associated with transient ischaemic attacks (more common with children) and stroke (haemorrhagic more typical in adults). They include headache, hemiparesis, seizures, disturbed consciousness, speech deficits (aphasia), sensory and cognitive impairments, involuntary movements, and vision problems.

Differential Diagnosis2
Associated Diseases

Associations have been made with leptospirosis, TB, certain anaemias, and vascular disorders causing intimal thickening including hypertension and atherosclerosis.
MMD also commoner in association with a mixed bag of congenital syndromes (Down's, Turner's, Marfan's, Apert's) and diseases (neurofibromatosis type I, tuberous sclerosis, Hirschsprung)

Investigations

If a patient has had a stroke and the aetiology is unclear, a hypercoagulability profile should be arranged including Protein C, Protein S, Antithrombin III, homocysteine and Factor V Leiden levels.
A raised erythrocyte sedimentation rate (ESR) may rule out vasculitis, but a normal ESR does not exclude this diagnosis.
The gold standard test is radio-imaging.2Findings suggestive of the diagnosis of MMD on CT scanning or magnetic resonance angiography (MRA) include:

  • Stenosis or occlusion at the terminal portion of the internal carotid artery or the proximal portion of the anterior or middle cerebral arteries
  • Abnormal vascular networks in the vicinity of the occluded or stenosed areas
  • The presence of these findings bilaterally
Management

Medical

There is little evidence that the disease process per se can be modified by drug therapy. If cerebral haemorrhage has occurred, strict control of blood pressure should be instituted. Patients who have sustained an ischaemic stroke or TIA should have the appropriate antiplatelet or anticoagulant therapy.2

Surgical

Procedures to enhance cerebral flow produce variable results3. Indirect revascularisation techniques, which rely on the development of collateral vessels to circumvent the block, seem to produce the best results in paediatric patients. The commonest technique, known as encephalomyoduroarteriosynangiosis (EMDAS) involves repositioning the richly vascularised temporalis muscle and the temporal artery along the lateral brain surface, and suturing them to the dura. For adult patients, the best technique seems to be direct shunting between the superficial temporal artery and the middle cerebral artery.4

Prognosis

Surgery improves the prognosis for patients presenting with cerebral ischaemia. However, for patients presenting with haemorrhage, the prognosis is poor. Progressive neurological deterioration and disability occur. Death is generally from haemorrhage in approximately 5% of children and 10% of adults.2


Document References
  1. Ikeda K, Iwasaki Y, Kashihara H, et al; Adult moyamoya disease in the asymptomatic Japanese population. J Clin Neurosci. 2006 Apr;13(3):334-8. Epub 2006 Mar 15. [abstract]
  2. Sucholeiki R, Chawla J; Moyamoya Disease eMedicine.com 2006
  3. Isono M, Ishii K, Kamida T, et al; Long-term outcomes of pediatric moyamoya disease treated by encephalo-duro-arterio-synangiosis. Pediatr Neurosurg. 2002 Jan;36(1):14-21. [abstract]
  4. Zipfel GJ, Fox DJ Jr, Rivet DJ; Moyamoya disease in adults: the role of cerebral revascularization. Skull Base. 2005 Feb;15(1):27-41. [abstract]

Internet and Further Reading Acknowledgements EMIS is grateful to Dr Laurence Knott for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 2470
Document Version: 20
DocRef: bgp1992
Last Updated: 20 Nov 2006
Review Date: 19 Nov 2008
Patient UK Current Health News








Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>








Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page